• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad, April 6

Torrent Pharmaceuticals Ltd has announced the launch of two new drugs, one for treatment of neuropathic pain and another drug that helps in reducing insulin resistance in Type-2 diabetes.

The new drugs — Pregeb (Pregabalin) and Piopod (Pioglitazone) — command a $2 billion and $1.5 billion share in the global market. Pregabalin is the latest therapy available for the treatment of neuropathic pain (which feels like pins being thrust in fingertips, a condition common in diabetes patients), while Pioglitazone is a trusted name in reducing insulin resistance in Type-2 diabetes, Torrent said in a release on Thursday. The two drugs have been launched by Azuca, Torrent's recently launched diabetes division.

More Stories on : New Products & Services | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Zee bags telecast rights in non-ICC member nations

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line